ASCO 2023: US-Mexico cross-border collaboration greatly improves paediatric leukaemia survival
Five-year overall survival improved by 30% for children with acute lymphoblastic leukaemia (ALL) who were…
Five-year overall survival improved by 30% for children with acute lymphoblastic leukaemia (ALL) who were…
Women with obesity when they are diagnosed with early breast cancer have a higher risk…
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median…
The AGITG and NHMRC CTC today announced that the INTEGRATE IIa study, a phase III…
A new precision radiotherapy technique described as ‘practice changing’ has been shown to reduce long-term…
Today’s episode of The Oncology Journal Club podcast series is an ASCO 2022 Special… Craig…
In a collaboration announced today, the American Society of Clinical Oncology, Inc.(ASCO) will work with…
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favourable…
The use of sacituzumab govitecan (Trodelvy) an antibody-drug conjugate, resulted in longer progression-free survival compared to…
Ibrutinib (Imbruvica) combined with bendamustine-rituximab improved progression-free survival by 50% for older patients with newly…